. 2023 Aug 21;83(21):3636–3649. doi: 10.1158/0008-5472.CAN-22-3402

Table 1.

Main clinical characteristics of participants in study.

		Age			Gender			TNM stage (%)
	Characteristics	Mean ± SD	Range	P	Male	Female	P	I–II	III–IV
Discovery (cohort I)	HC (n = 50)	53 ± 13	31–82	0.013	20 (40%)	30 (60%)	0.420	/	/
	CRC (n = 50)	59 ± 12	26–76		24 (48%)	26 (52%)		33 (66%)	17 (34%)
Biological validation I (cohort II)	HC (n = 83)	61 ± 7	45–81	0.537	40 (48%)	43(52%)	0.316	/	/
	CRC (n = 84)	62 ± 10	39–81		47 (56%)	37 (44%)		43 (51%)	41 (49%)
Biological validation II (cohort III)	HC (n = 38)	59 ± 9	35–75	0.194	16 (42%)	22 (58%)	0.853	/	/
	AA (n = 11)	62 ± 6	51–68		4 (36%)	7 (64%)		/	/
	eCRC (n = 44)	62 ± 8	45–77		20 (45%)	24 (55%)		44 (100%)	0 (0%)
Performance evaluation of multi-msqPCR (cohort IV)	HC (n = 42)	62 ± 8	42–79	0.677	24 (57%)	18 (43%)	0.766	/	/
	eCRC (n = 39)	61 ± 9	40–79		21 (54%)	18 (46%)		39 (100%)	0 (0%)
CDM development and evaluation (cohort V)	HC (n = 179)	57 ± 9	35–79	0.181	87 (49%)	92 (51%)	0.236^a	/	/
	Non-AA (n = 52)	58 ± 12	23–76		33 (63%)	19 (37%)		/	/
	AA (n = 46)	58 ± 8	36–72		24 (52%)	22 (48%)		/	/
	eCRC (n = 170)	59 ± 12	30–79		100 (59%)	70 (41%)		170 (100%)	0 (0%)
	eGC (n = 63)	58 ± 10	33–77		39 (62%)	24 (38%)		63 (100%)	0 (0%)
	eBC (n = 55)	57 ± 11	34–78		0 (0%)	55 (100%)		55 (100%)	0 (0%)
	eLC (n = 62)	59 ± 9	33–72		34 (55%)	28 (45%)		62 (100%)	0 (0%)

Abbreviations: AA, advanced adenomas; CDM, CRC diagnostic model; CRC, colorectal cancer; eBC, early-stage breast cancer; eCRC, early-stage colorectal cancer; eGC, early-stage gastric cancer; eLC, early-stage lung cancer; HC, healthy controls; Non-AA, non–advanced adenomatous polyps.

^aBreast cancer was excluded in the statistical analysis of gender differences between groups.